RxDoctor Payments Data

Avinash Khitri, MD

Interventional Cardiology · Covina, CANPI 1326246018

Payments from drug & device makers

$16,152in general payments, 2019–2025

Across 713 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novartis$2K
  • Abiomed$2K
  • Pfizer$981
  • Inari Medical, Inc.$851
  • AstraZeneca$739
  • plus $7K from 37 others
$219in research payments, 2019–2025

Across 2 payments — averaging $109.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$219

What the payments were for

  • Food & beverage$16,140100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,152 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$398,145
Medicare patients
966
Services billed
3,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban277$310,018
EntrestoSacubitril/Valsartan132$156,096
FarxigaDapagliflozin Propanediol124$138,046
JardianceEmpagliflozin68$69,690
BrilintaTicagrelor80$66,517
Repatha SureclickEvolocumab40$45,055
XareltoRivaroxaban17$23,005
Praluent PenAlirocumab14$19,426
MultaqDronedarone Hcl18$14,024
Repatha SyringeEvolocumab24$12,495
Metoprolol Succinate369$5,614
Atorvastatin Calcium443$5,158
Irbesartan131$2,755
Rosuvastatin Calcium150$2,630
Ezetimibe91$2,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$981$310,018277 claims
AstraZenecaFarxiga, Brilinta$739$204,564204 claims
NovartisEntresto$2,208$156,096132 claims
Boehringer IngelheimJardiance$199$69,69068 claims
Johnson & JohnsonXarelto$421$23,00517 claims
Sanofi-aventis U.S. LLCMultaq$194$14,02418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →